Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women

Cancer Research

Volumn 73, Issue 2, 2013, Pages 767-775

  Passarelli, Michael N ^a,b   Phipps, Amanda I ^a   Potter, John D ^a,b,c   Makar, Karen W ^a   Coghill, Anna E ^a,b   Wernli, Karen J ^d   White, Emily ^a,b   Chan, Andrew T ^e,f   Hutter, Carolyn M ^a,b   Peters, Ulrike ^a,b   Newcomb, Polly A ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b University of Washington School of Public Health   (United States)

^c MASSEY UNIVERSITY   (New Zealand)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ADULT; AGED; ALLELE; ANDROGEN RECEPTOR GENE; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ESTROGEN RECEPTOR ALPHA GENE; ESTROGEN RECEPTOR BETA GENE; FEMALE; FOLLOW UP; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGESTERONE RECEPTOR GENE; PROMOTER REGION; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ESTROGEN RECEPTOR BETA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PROMOTER REGIONS, GENETIC;

EID: 84872539783     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2484     Document Type: Article

References (50)

1. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980;65: 1201-7.
2. Thun MJ, Calle EE, Namboodiri MM, Flanders WD, Coates RJ, Byers T, et al. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 1992;84: 1491-500.
3. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106: 574-82.
4. Slattery ML, Anderson K, Samowitz W, Edwards SL, Curtin K, Caan B, et al. Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA). Cancer Causes Control 1999;10: 467-73.
5. Coghill AE, NewcombPA, Chia VM, Zheng Y, Wernli KJ, Passarelli MN, et al. Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. Br J Cancer 2011;104: 763-8.
6. Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24: 5680-6.
7. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350: 991-1004.
8. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008;17: 2609-18.
9. Prentice RL, Pettinger M, Beresford SA, Wactawski-Wende J, Hubbell FA, Stefanick ML, et al. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev 2009;18: 1531-7.
10. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999;261: 521-7.
11. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001;61: 632-40.
12. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7: 536-40.
13. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000; 60: 245-8.
14. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003;39: 1251-8.
15. Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol Rep 2005;14: 17-21.
16. Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schonfels W, et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 2011;18: 265-76.
17. Lin J, Zee RY, Liu KY, Zhang SM, Lee IM, Manson JE, et al. Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women. Cancer Causes Control 2010;21: 897-908.
18. Lin JH, Manson JE, Kraft P, Cochrane BB, Gunter MJ, Chlebowski RT, et al. Estrogen and progesterone-related gene variants and colorectal cancer risk in women. BMC Med Genet 2011;12: 78.
19. Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, et al. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 2011;12: 27-39.
20. Press OA, Zhang W, Gordon MA, Yang D, Haiman CA, Azuma M, et al. Gender-related survival differences associated with polymorphic variants of estrogen receptor-beta (ERbeta) in patients with metastatic colon cancer. Pharmacogenomics J 2011;11: 375-82.
21. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 2007; 67: 7534-9.
22. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74: 106-20.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc Ser B 1995: 289-300.
24. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19: 61-109.
25. White E, Patterson RE, Kristal AR, Thornquist M, King I, Shattuck AL, et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 2004;159: 83-93.
26. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5: 388-96.
27. Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, et al. Association between colorectal cancer susceptibility loci and survival time following diagnosis with colorectal cancer. Gastroenterology 2012;43: 51-4.e4.
28. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34: 816-34.
29. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet 2012;131: 217-34.
30. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JÅ, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERa and ERb at AP1 sites. Science. 1997;277: 1508-10.
31. Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, et al. Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci U S A 2006;103: 2959-64.
32. Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 17Beta-estradiol induces ERbeta up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun 2007;359: 102-7.
33. Giroux V, Bernatchez G, Carrier JC. Chemopreventive effect of ERbeta-Selective agonist on intestinal tumorigenesis in Apc(Min/+) mice. Mol Carcinog 2011;50: 359-69.
34. Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC. Oestrogeninduced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol 2002;174: 369-77.
35. Edvardsson K, Strom A, Jonsson P, Gustafsson JA, Williams C. Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 2011;25: 969-79.
36. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Strom A, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009;69: 6100-6.
37. Elbanna HG, Ebrahim MA, Abbas AM, Zalata K, Hashim MA. Potential value of estrogen receptor Beta expression in colorectal carcinoma: interaction with apoptotic index. J Gastrointest Cancer 2012;43: 56-62.
38. Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, et al. Prognostic impact of ERbeta and MMP7 expression on overall survival in colon cancer. Tumour Biol 2010;31: 651-8.
39. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H. Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis 2009;24: 613-22.
40. Sato R, Suzuki T, Katayose Y, Miura K, Shiiba K, Tateno H, et al. Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors. Cancer Res 2009;69: 914-22.
41. Honma N, Arai T, Takubo K, Younes M, Tanaka N, Mieno MN, et al. Oestrogen receptor-beta CA repeat polymorphism is associated with incidence of colorectal cancer among females. Histopathology 2011;59: 216-24.
42. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, et al. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2936-42.
43. Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT. ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 2005;207: 53-60.
44. Li LC, Yeh CC, Nojima D, Dahiya R. Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun 2000;275: 682-9.
45. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003;22: 7600-6.
46. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 2000;60: 702-6.
47. Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, et al. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 50-untranslated region in human epithelial ovarian carcinoma. Cancer Sci. 2008;99: 2365-72.
48. Treeck O, Elemenler E, Kriener C, Horn F, Springwald A, Hartmann A, et al. Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 2009;114: 207-11.
49. Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F, Augustsson- Balter K, Adami HO, et al. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res 2006;12: 1936-41.
50. Philips S, Richter A, Oesterreich S, Rae JM, Flockhart DA, Perumal NB, et al. Functional characterization of a genetic polymorphism in the promoter of the ESR2 gene. Horm Cancer 2012;3: 37-43.